Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2008 First Published: 5/23/2003


1.		Phase I/II Study of BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				BIOCRYST-1777BC-103 NCT00061880


2.		Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Any age				Pharmaceutical / Industry				BCX1777-Bi-04-106 NCT00289562

Last Modified: 6/2/2008 First Published: 6/23/2004


3.		Phase II Study of Forodesine in Patients With Recurrent or Refractory Advanced T-Cell Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Any age				Pharmaceutical / Industry				BIOCRYST-BCX1777-T-04-201 NCT00095381, UCLA-0404017-01


4.		Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				BCX1777-Bo-05-204 NCT00289549


5.		Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				BCX1777-Tio-05-202 NCT00419081

Last Modified: 7/12/2007 First Published: 7/26/2003


6.		Phase I Study of BCX-1777 in Patients With Refractory Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				16 and over				Pharmaceutical / Industry				BIOCRYST-1777BC-102 NCT00066235

Last Modified: 1/29/2008 First Published: 11/20/2003


7.		Phase I Study of BCX-1777 in Patients With Refractory T-Cell or Non-T-Cell Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				BIOCRYST-1777BC-101 CCF-5909, NCT00073944

Last Modified: 7/10/2007 First Published: 11/15/2004


8.		Phase I Study of Forodesine (BCX-1777) in Patients With Refractory Stage IIA-IVB Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				BIOCRYST-BCX1777-C-04-105 NCT00098332

Select All on One Page